Publikationen von Odette Wegwarth

McDowell, M. E., Gigerenzer, G., Wegwarth, O., & Rebitschek, F. G. (2019). Effect of tabular and icon fact box formats on comprehension of benefits and harms of prostate cancer screening: A randomized trial. Medical Decision Making, 39(1), 41–56. https://doi.org/10.1177/0272989X18818166

Rebitschek, F. G., Pashayan, N., Widschwendter, M., & Wegwarth, O. (2019). Do cancer risk and benefit-harm ratios influence women's consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries. PLoS ONE, 14(6), Article e0218188. https://doi.org/10.1371/journal.pone.0218188

Rebitschek, F. G., Reisel, D., Lein, I., & Wegwarth, O. (2019). Epigenetic risk assessment of female cancers: Women's information needs and attitudes. Public Health Genomics, 22(1-2), 46–57. https://doi.org/10.1159/000501975

Wegwarth, O., Pashayan, N., Widschwendter, M., & Rebitschek, F. G. (2019). Women's perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: A cross-sectional online survey. BMC Public Health, 19, Article 667. https://doi.org/10.1186/s12889-019-6994-8

Mühlbauer, V., Prinz, R., Mühlhauser, I., & Wegwarth, O. (2018). Alternative package leaflets improve people's understanding of drug side effects - A randomized controlled exploratory survey. PLoS ONE, 13(9), Article e0203800. https://doi.org/10.1371/journal.pone.0203800

Wegwarth, O. (2018). Brustkrebsfrüherkennung - Nutzen und Risiken richtig kommunizieren. Der Gynäkologe, 51(5), 370–379. https://doi.org/10.1007/s00129-018-4199-3

Wegwarth, O., & Gigerenzer, G. (2018). US gynecologists' estimates and beliefs regarding ovarian cancer screening's effectiveness 5 years after release of the PLCO evidence. Scientific Reports, 8, Article 17181. https://doi.org/10.1038/s41598-018-35585-z

Wegwarth, O., Widschwendter, M., Cibula, D., Sundström, K., Portuesi, R., Lein, I., Rebitschek, F. G., & FORECEE (4C) Consortium. (2018). What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open, 8, Article e023789. https://doi.org/10.1136/bmjopen-2018-023789

Widschwendter, M., Jones, A., Evans, I., Reisel, D., Dillner, J., Sundström, K., Steyerberg, E. W., Vergouwe, Y., Wegwarth, O., Rebitschek, F. G., Siebert, U., Sroczynski, G., de Beaufort, I. D., Bolt, I., Cibula, D., Zikan, M., Bjørge, L., Colombo, N., Harbeck, N., Dudbridge, F., Tasse, A.-M., Knoppers, B. M., Joly, Y., Teschendorff, A. E., Pashayan, N., & the FORECEE (4C) Consortium. (2018). Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 15(5), 292–309. https://doi.org/10.1038/nrclinonc.2018.30

Donner-Banzhoff, N., Seidel, J., Sikeler, A. M., Bösner, S., Vogelmeier, M., Westram, A., Feufel, M., Gaissmaier, W., Wegwarth, O., & Gigerenzer, G. (2017). The phenomenology of the diagnostic process: A primary-care based survey. Medical Decision Making, 37(1), 27–34. https://doi.org/10.1177/0272989X16653401